Tekla Capital Management LLC lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 39.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 449,255 shares of the biotechnology company’s stock after buying an additional 126,000 shares during the quarter. Tekla Capital Management LLC owned about 0.46% of BioCryst Pharmaceuticals worth $2,206,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. Rock Springs Capital Management LP lifted its holdings in BioCryst Pharmaceuticals by 80.6% in the 4th quarter. Rock Springs Capital Management LP now owns 812,500 shares of the biotechnology company’s stock valued at $3,989,000 after purchasing an additional 362,500 shares in the last quarter. RTW Investments LP lifted its holdings in shares of BioCryst Pharmaceuticals by 1.4% during the 4th quarter. RTW Investments LP now owns 3,372,674 shares of the biotechnology company’s stock worth $16,560,000 after acquiring an additional 47,969 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 74.9% during the 4th quarter. Renaissance Technologies LLC now owns 396,203 shares of the biotechnology company’s stock worth $1,945,000 after acquiring an additional 169,700 shares during the period. Emory University lifted its holdings in shares of BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Emory University now owns 383,768 shares of the biotechnology company’s stock worth $1,884,000 after acquiring an additional 23,726 shares during the period. Finally, Geode Capital Management LLC increased its position in BioCryst Pharmaceuticals by 9.6% during the 4th quarter. Geode Capital Management LLC now owns 819,415 shares of the biotechnology company’s stock worth $4,023,000 after purchasing an additional 71,665 shares in the last quarter. 91.74% of the stock is currently owned by institutional investors and hedge funds.
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down $0.01 on Friday, reaching $5.37. The company had a trading volume of 937,650 shares, compared to its average volume of 950,964. BioCryst Pharmaceuticals, Inc. has a 1 year low of $3.95 and a 1 year high of $9.25. The stock has a market cap of $530.50, a PE ratio of -6.88 and a beta of 2.63. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.68 and a quick ratio of 2.53.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. The business had revenue of $3.89 million for the quarter, compared to analyst estimates of $6.07 million. During the same quarter in the previous year, the business posted ($0.06) earnings per share. The company’s revenue was down 56.7% compared to the same quarter last year. equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.79 EPS for the current year.
A number of analysts recently issued reports on the stock. BidaskClub raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 6th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. ValuEngine cut BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 14th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. Finally, Royal Bank of Canada upgraded BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research note on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $8.29.
COPYRIGHT VIOLATION NOTICE: “BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Position Increased by Tekla Capital Management LLC” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/17/tekla-capital-management-llc-has-2-21-million-stake-in-biocryst-pharmaceuticals-inc-bcrx.html.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.